ArticleDigital health
Feasibility and acceptability of FinCare: A personalized online tool for estimating out-of-pocket costs for cancer treatment.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Patients with cancer need to make complex treatment decisions that weigh benefit, risk, and increasingly, treatment costs. Although patients desire to have information about out-of-pocket (OOP) spending to help inform such decisions, individualized OOP cost information is rarely discussed in clinical practice and often difficult for patients to access. FinCare, an online tool for generating patient-specific OOP cost estimates, was developed to address this gap. This pilot study evaluated the feasibility and acceptability of FinCare among patients receiving cancer therapy. Methods: Patients (n=10) beginning a new cancer therapy regimen were recruited to provide feedback and input. Participants' treatment and insurance information were entered into FinCare to generate individualized OOP cost estimates. After reviewing the report, participants rated its usefulness and their satisfaction with this online tool. Secondary outcomes of financial toxicity and anxiety were also assessed. Results: FinCare successfully generated individualized monthly OOP estimates for all participants (range: $0-$2172.34/month). Acceptability was high, with 80%-90% endorsing its ease of use and high satisfaction with the information received. Qualitative comments indicated that participants found the information to be clear and helpful for planning. Receipt of individualized cost information did not result in significant changes in financial toxicity or anxiety. Conclusions: FinCare was feasible to implement and acceptable to patients starting a new cancer regimen. Receipt of individualized OOP cost estimates was reported to be useful and did not increase participant anxiety. Study findings, however, are limited by the small sample of patients from a single insurer and a single academic institution. Future studies comprised of larger, more diverse patient populations from multiple insurer groups and centers are warranted to demonstrate the broader feasibility and utility of this tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.